Patient Name : Ms.

PRIYA SINGH Collected : 29/Nov/2023 07:35AM

Age/Gender : 27 Y 10 M 4 D /F Received : 29/Nov/2023 12:33PM
UHID/MR No : APJ1.0022161054 Reported : 29/Nov/2023 01:24PM
Visit ID : DRELOPV599 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PUP 24X7_CREDIT
IP/OP NO : Patient location : DLF Phase II,GURGAON

DEPARTMENT OF BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Range Method

HBA1C, GLYCATED HEMOGLOBIN , 5.6 % HPLC

WHOLE BLOOD EDTA
ESTIMATED AVERAGE GLUCOSE (eAG) , 114 mg/dL Calculated
WHOLE BLOOD EDTA

Comment:
Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:
REFERENCE GROUP HBA1C %
NON DIABETIC <5.7
PREDIABETES 5.7 – 6.4
DIABETES ≥ 6.5
DIABETICS
EXCELLENT CONTROL 6–7
FAIR TO GOOD CONTROL 7–8
UNSATISFACTORY CONTROL 8 – 10
POOR CONTROL >10
Note: Dietary preparation or fasting is not required.
1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic
Control by American Diabetes Association guidelines 2023.
2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation
is advised in interpretation of low Values.
4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age.
HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
A: HbF >25%
B: Homozygous Hemoglobinopathy.
(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 1 of 5

SIN No:BI17156195
Patient Name : Ms.PRIYA SINGH Collected : 29/Nov/2023 07:35AM
Age/Gender : 27 Y 10 M 4 D /F Received : 29/Nov/2023 12:33PM
UHID/MR No : APJ1.0022161054 Reported : 29/Nov/2023 02:07PM
Visit ID : DRELOPV599 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PUP 24X7_CREDIT
IP/OP NO : Patient location : DLF Phase II,GURGAON

DEPARTMENT OF IMMUNOLOGY
Test Name Result Unit Bio. Ref. Range Method

THYROID PROFILE TOTAL (T3, T4, TSH) , SERUM

TRI-IODOTHYRONINE (T3, TOTAL) 1.2 ng/mL 0.7-2.04 CLIA
THYROXINE (T4, TOTAL) 10.24 µg/dL 5.48-14.28 CLIA
THYROID STIMULATING HORMONE 7.510 µIU/mL 0.34-5.60 CLIA
(TSH)
Kindly correlate clinically

Comment:
Bio Ref Range for TSH in uIU/ml (As per American
For pregnant females
Thyroid Association)
First trimester 0.1 - 2.5
Second trimester 0.2 – 3.0
Third trimester 0.3 – 3.0
1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine).
Increased blood level of T3 and T4 inhibit production of TSH.
2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often
referred to as sub-clinical hypo- or hyperthyroidism respectively.
3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small
fraction of circulating hormone is free and biologically active.
4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.
TSH T3 T4 FT4 Conditions
High Low Low Low Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement
High N N N
Therapy.
N/Low Low Low Low Secondary and Tertiary Hypothyroidism
Low High High High Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low N N N Subclinical Hyperthyroidism
Low Low Low Low Central Hypothyroidism, Treatment with Hyperthyroidism
Low N High High Thyroiditis, Interfering Antibodies
N/Low High N N T3 Thyrotoxicosis, Non thyroidal causes
High High High High Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 2 of 5

SIN No:IM06540190
Patient Name : Ms.PRIYA SINGH Collected : 29/Nov/2023 07:35AM
Age/Gender : 27 Y 10 M 4 D /F Received : 29/Nov/2023 12:33PM
UHID/MR No : APJ1.0022161054 Reported : 29/Nov/2023 02:07PM
Visit ID : DRELOPV599 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PUP 24X7_CREDIT
IP/OP NO : Patient location : DLF Phase II,GURGAON

DEPARTMENT OF IMMUNOLOGY
Test Name Result Unit Bio. Ref. Range Method

PROLACTIN , SERUM 26.04 ng/mL CLIA

Comment:
REFERENCE GROUP REFERENCE RANGE IN ng/ml
ADULT FEMALES
PRE-MENOPAUSAL 3.3 – 26.7
PREGNANCY 9.7 – 208.5
POST MENOPAUSAL 2.7 – 19.6
MALES 2.6 – 13.1

Normal prolactin secretion varies with time, which results in serum prolactin levels two to three times higher at night than during the
day.
Serum prolactin levels during the menstrual cycle are variable and commonly exhibit slight elevations during the mid-cycle.
Prolactin levels in normal individuals tend to rise in response to physiologic stimuli including sleep, exercise, nipple stimulation,
sexual intercourse, hypoglycemia, pregnancy, and surgical stress.
Prolactin values that exceed the reference values may be due to macroprolactin (prolactin bound to immunoglobulin).
Macroprolactin should be evaluated if signs and symptoms of hyperprolactinemia are absent or pituitary imaging studies are not
informative.
Increased levels of prolactin upto 100ng/mL are documented with the use of following drugs: Neuroleptics, antidepressants,
antipsychotics, medications for nausea such as metoclopramide, birth control pills, estrogen analogs, dopamine antagonists, some
blood pressure medications like methyldopa, reserpine, and opiates.

Page 3 of 5

SIN No:IM06540190
Patient Name : Ms.PRIYA SINGH Collected : 29/Nov/2023 07:35AM
Age/Gender : 27 Y 10 M 4 D /F Received : 29/Nov/2023 04:07PM
UHID/MR No : APJ1.0022161054 Reported : 29/Nov/2023 05:35PM
Visit ID : DRELOPV599 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PUP 24X7_CREDIT
IP/OP NO : Patient location : DLF Phase II,GURGAON

DEPARTMENT OF IMMUNOLOGY
Test Name Result Unit Bio. Ref. Range Method

TESTOSTERONE, TOTAL , SERUM 95.28 ng/dL 11-59 CLIA

Kindly correlate clinically.

Comment:
Testosterone exhibits significant circadian variations in young men, and early morning samples are recommended.
Increased levels are seen in precocious puberty (males), androgen resistance, CAH, ovarian stromal hyperthecosis.
Decreased levels are seen in delayed puberty (males), gonadotropin deficiency, testicular feminization, estrogen therapy and
certain systemic diseases

Page 4 of 5

SIN No:IM06541771
Patient Name : Ms.PRIYA SINGH Collected : 29/Nov/2023 07:35AM
Age/Gender : 27 Y 10 M 4 D /F Received : 30/Nov/2023 02:56PM
UHID/MR No : APJ1.0022161054 Reported : 30/Nov/2023 05:04PM
Visit ID : DRELOPV599 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PUP 24X7_CREDIT
IP/OP NO : Patient location : DLF Phase II,GURGAON

DEPARTMENT OF IMMUNOLOGY
Test Name Result Unit Bio. Ref. Range Method

TESTOSTERONE- FREE , SERUM 2.95 pg/mL <4.2 CLIA

Comment:
Usually, bioavailable and free testosterone levels parallel the total testosterone levels. However, a number of conditions and
medications are known to increase or decrease the sex hormone-binding globulin (SHBG) concentration, which may cause total
testosterone concentration to change without necessarily influencing the bioavailable or free testosterone concentration, or vice
versa.

Treatment with corticosteroids and sex steroids (particularly oral conjugated estrogen) can result in changes in SHBG levels and
availability of sex-steroid binding sites on SHBG. In polycystic ovarian syndrome and related conditions, there is often significant
insulin resistance, which is associated with low SHBG levels. Consequently, bioavailable or free testosterone levels may be more
significantly elevated.

The correlation coefficient between bioavailable and free testosterone (by equilibrium dialysis) is 0.9606

*** End Of Report ***

Page 5 of 5

SIN No:IM06541772
This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory,Hyderabad